Inhibitory B7-family molecules in the tumour microenvironment
Top Cited Papers
- 1 June 2008
- journal article
- review article
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 8 (6) , 467-477
- https://doi.org/10.1038/nri2326
Abstract
The B7 family consists of activating and inhibitory co-stimulatory molecules that positively and negatively regulate immune responses. Recent studies have shown that human and rodent cancer cells, and stromal cells and immune cells in the cancer microenvironment upregulate expression of inhibitory B7 molecules and that these contribute to tumour immune evasion. In this Review, we focus on the roles of these B7 molecules in the dynamic interactions between tumours and the host immune system, including their expression, regulation and function in the tumour microenvironment. We also discuss novel therapeutic strategies that target these inhibitory B7 molecules and their signalling pathways to treat human cancer.Keywords
This publication has 131 references indexed in Scilit:
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006
- Checkpoint Blockade in Cancer ImmunotherapyPublished by Elsevier ,2006
- Costimulatory molecule B7‐H1 in primary and metastatic clear cell renal cell carcinomaCancer, 2005
- Regulation of immune responses by L-arginine metabolismNature Reviews Immunology, 2005
- Mechanisms and functional significance of tumour-induced dendritic-cell defectsNature Reviews Immunology, 2004
- Inflammation and necrosis promote tumour growthNature Reviews Immunology, 2004
- Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunityNature Reviews Immunology, 2004
- BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1Nature Immunology, 2003
- Inflammation and cancerNature, 2002